Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Abstract
- Volume: 39 Issue: 15
- Publication Date: 2021
- Doi Number: 10.1200/jco.2021.39.15_suppl.9085
- Journal Name: JOURNAL OF CLINICAL ONCOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, CAB Abstracts, CINAHL, EMBASE, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
- Hacettepe University Affiliated: Yes